

DIASORIN LAUNCHES THE NEW N-TACT PTH GEN II ON ITS LIAISON PLATFORM WORLDWIDE

February 18, 2014 - Saluggia (VC) - **DiaSorin** (FTSE Mid Cap:DIA) is pleased to announce the launch of a new product in its portfolio, the **LIAISON N-TACT PTH Gen II assay**, for the **quantitative determination of intact human parathyroid hormone (PTH)** in human serum and plasma.

The LIAISON N-TACT PTH Gen II assay is a **redevelopment** of our existing N-TACT PTH assays and employs specific polyclonal antibodies to assist in **diagnosis of disorders of calcium metabolism**. This assay is an **addition** to the current DiaSorin **LIAISON Bone and Mineral menu** made of both specialty and main stream tests such as the 25-OH Vitamin D TOTAL Assay, 1-84 PTH, BAP OSTASE and Osteocalcin.

Francesco Colotta, Senior Corporate V.P and Chief Medical Officer in DiaSorin, explained:” *The main function of PTH is to **regulate serum calcium levels** within the body; when serum calcium levels are **high**, the parathyroid glands, located at the back of the thyroid gland, are stimulated to **decrease the production of PTH** which lowers serum calcium levels; when serum calcium levels are **low**, **PTH secretion is increased**. In cases when this process is not functioning correctly, the consequence is a condition called **Hyperparathyroidism**, which is caused by the over secretion of PTH by the parathyroid glands”.*

Primary hyperparathyroidism is characterized by **abnormal over secretion** of parathyroid hormone typically as a result of a parathyroid tumor. According to recent studies, its prevalence in the general population is estimated **less than 1%**. Whereas **secondary hyperparathyroidism** is an appropriately **high PTH level**, which is caused by disorders of calcium and phosphate metabolism. Secondary hyperparathyroidism is commonly found in patients suffering from **chronic kidney disease** which is a growing health issue with an estimated prevalence **exceeding 10% worldwide**.

According to EDMA analysis and an internal estimation, the **potential Market in Europe and USA** for the LIAISON N-TACT PTH Gen II assay is around **€43 million**.

REFERENCE TABLE FOR DIASORIN PRODUCTS

| | | | |
|------------------|------------------------------------------------------------------------------------|---|-------------------------|
| Assay name | LIAISON N-TACT PTH Gen II | | |
| Diagnosis | quantitative determination of intact human parathyroid hormone in serum and plasma | | |
| Business segment | Immunodiagnosics | ✓ | Molecular Diagnostics |
| Potential market | € 43 mIn in Europe and USA | | |
| Technology | CLIA | ✓ | Extraction |
| | ELISA | | Amplification/Detection |
| | RIA | | HLA Typing |
| Clinical Area | Infectious Disease | | Infectious Disease |
| | Hepatitis and Retroviruses | | |
| | Oncology & Endocrinology | | Onco-hematology |
| | Bone & Mineral | ✓ | |
| | Cardiac Markers | | |
| GI Stool Testing | | | |

Carlo Rosa, CEO of DiaSorin Group, commented :*"With this new assay we demonstrate once again our commitment in providing tests that guarantee accuracy of results. Furthermore the new launch in the Bone and Mineral clinical area clearly shows our aim to strengthen our positioning in this segment worldwide and in particular in the United States where we are already known for our Endocrinology and Bone and Mineral products and where we plan to be a key player."*

About DiaSorin

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD "diagnostics specialist".

For additional information, please contact:**Riccardo Fava**

External Relations Director - Head of IR and Media

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Margherita Sacerdoti

Investor Relations Specialist

Tel: +39.0161.487456

margherita.sacerdoti@diasorin.it